Immediate reopening of acutely occluded coronary arteries via primary percutaneous
coronary intervention (PCI) is the treatment of choice to salvage the ischemic myocardium in …

FX06 (fibrin derived peptide Bβ15-42) is a promising new drug candidate indicated for the
prevention of reperfusion injury in patients undergoing primary percutaneous intervention …

Several novel interventional and pharmacological therapeutic approaches have been
examined in recent years for the prevention of ischemia/reperfusion injury in myocardial …

Objectives: The purpose of this study was to investigate whether FX06 would limit infarct size
when given as an adjunct to percutaneous coronary intervention. Background: FX06, a …

Objective: The fibrin-derived peptide Bβ 15–42 has been shown to reduce infarct size in
rodent models of ischemia-reperfusion injury. To increase its potential for translation into the …

Many compounds have been shown to prevent reperfusion injury in various animal models,
although to date, translation into clinic has revealed several obstacles. Therefore, the …

Aim ITF-1697 is a C-reactive protein-derived tetrapeptide that, based on pre-clinical studies,
is thought to reduce reperfusion injury. We performed a dose-finding study to assess safety …

Background. The inflammatory response after prolonged ischemia and subsequent
reperfusion leads to increased risk of primary organ dysfunction after cardiac …

Objective: The fibrin-derived peptide Bβ 15-42 (also called FX06) has been shown to reduce
myocardial infarct size following ischemia/reperfusion. Hemorrhagic shock (HS) followed by …

Objectives: The fibrin-derived peptide Bβ 15–42 (FX06) has been proven to attenuate
ischemia/reperfusion injury. We tested the hypothesis that Bβ 15–42 improves survival rate …